CN117402214B - Influenza A virus CD8+ T cell epitope peptide and application thereof - Google Patents
Influenza A virus CD8+ T cell epitope peptide and application thereof Download PDFInfo
- Publication number
- CN117402214B CN117402214B CN202311379350.9A CN202311379350A CN117402214B CN 117402214 B CN117402214 B CN 117402214B CN 202311379350 A CN202311379350 A CN 202311379350A CN 117402214 B CN117402214 B CN 117402214B
- Authority
- CN
- China
- Prior art keywords
- influenza
- virus
- epitope peptide
- antigen
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 109
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 83
- 241000712431 Influenza A virus Species 0.000 title claims abstract description 73
- 239000000427 antigen Substances 0.000 claims abstract description 77
- 108091007433 antigens Proteins 0.000 claims abstract description 67
- 102000036639 antigens Human genes 0.000 claims abstract description 67
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims abstract description 26
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims abstract description 26
- 229960005486 vaccine Drugs 0.000 claims abstract description 24
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 238000004153 renaturation Methods 0.000 claims description 5
- 238000002255 vaccination Methods 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 238000012827 research and development Methods 0.000 abstract description 6
- 230000007969 cellular immunity Effects 0.000 abstract description 4
- 230000005847 immunogenicity Effects 0.000 abstract description 4
- 238000009169 immunotherapy Methods 0.000 abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 206010022000 influenza Diseases 0.000 description 16
- 241000700605 Viruses Species 0.000 description 12
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 10
- 230000028993 immune response Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 7
- 239000000178 monomer Substances 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 208000037797 influenza A Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000011786 HLA-A Antigens Human genes 0.000 description 3
- 108010075704 HLA-A Antigens Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 102100030385 Granzyme B Human genes 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101710199771 Matrix protein 1 Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9446—Antibacterials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
The invention belongs to the technical field of immunotherapy, and particularly relates to an influenza A virus CD8+ T cell epitope peptide and application thereof. The technical problem to be solved by the invention is that a T cell epitope peptide for a universal influenza A virus vaccine is not developed in the field of influenza A virus at present. The technical scheme of the invention is that the amino acid sequence of the epitope peptide of the influenza A virus CD8+T cell is shown as SEQ ID No. 11. The antigen epitope peptide provided by the invention has strong immunogenicity and can induce antigen-specific CD8+T cells; it can assemble into pMHC complex with HLA-A2 heavy chain and HLA-A2 light chain beta 2m protein; or directly loaded to antigen presenting cells, can activate T cells, effectively induce T cell immunity, and can be used for research and development of influenza A virus universal vaccines, preparation and drug research and development and clinical treatment.
Description
Technical Field
The invention belongs to the technical field of immunotherapy, and particularly relates to an influenza A virus CD8+ T cell epitope peptide and application thereof.
Background
Seasonal influenza and its complications caused by influenza a virus (influenza A virus, IAV, hereinafter referred to as influenza a virus) remain a major threat to human health. According to statistics of world health organization, the annual seasonal influenza infection rate of the world is up to 5-15%, about 3 hundred million to 10 hundred million people are infected with influenza, and up to 25-50 ten thousand people die from influenza, and the death rate is up to 0.1%.
Because of the lack of effective antiviral drugs, the treatment of influenza and its complications is mainly symptomatic. Vaccination is a relatively effective prophylactic measure at present, mostly inducing the active production of protective antibodies by the body. However, since influenza a virus is a single-stranded antisense RNA virus, it is highly susceptible to mutation, resulting in antigen drift (antigenic drift) and antigen shift (antigenic shift), disabling neutralizing antibodies, and thus rendering the vaccine ineffective. Correspondingly, the cellular immune response recognizes highly conserved presentation antigens, thus exhibiting a high cross-protective capacity between different influenza a virus subtypes. For example, the cd8+ T cell immune response specific for Influenza A Virus (IAV) Matrix Protein 1 (M1) 58 to gilfveftl at position 66 (M158-66 GIL, abbreviated GIL) was found to occupy up to 80% of the anti-influenza a virus immune response. Therefore, the research on the cellular immune response of the anti-influenza A virus is expected to better understand the mechanism of antiviral immunity, and provides theoretical and experimental basis for developing broad-spectrum efficient anti-influenza A virus vaccine.
In view of the continuous occurrence of current influenza A virus variation, the method provides a trigger for developing universal influenza A virus vaccines and broad-spectrum therapeutic drugs in the future. The universal vaccine is a broad-spectrum vaccine which can effectively protect the characteristics of immune crowd even after the virus antigen is mutated. Therefore, development of a general vaccine and a broad-spectrum therapeutic drug that can still provide effective immune protection for vaccine immunized people after various variants of influenza a virus occur is urgent.
Studies show that the T cell immune response plays an important role in the antiviral defense of organisms after virus infection and in the immune pathological injury process of organisms, in particular CD8+ T cells, the antigen specific immune activity of which still exists after 11 years, and the important role of the CD8+ T cell immune response in the immune defense against influenza A virus and the important role of the CD8+ T cell immune response in vaccine development are demonstrated. The first step in the cd8+ T cell immune response is the specific recognition of epitope peptides presented by the virus-infected cells by T cells through their surface antigen recognition receptors. Therefore, the epitope peptide is an important key molecule for specifically recognizing viruses and playing an immune protection role by T cells, and is a key targeting molecule for immunodetection, immunotherapy and vaccine development.
CD8+ T cells recognize pMHC activation through T Cell Receptor (TCR), kill virus infected cells, clear virus, thereby exerting antiviral cellular immunity. Therefore, the identification of the epitope peptide capable of effectively activating the T cells can still induce effective T cell immune protection after the influenza A virus antigen is mutated, and is one of the keys for developing universal influenza A virus vaccines and broad-spectrum therapeutic medicaments.
Immune escape is the antagonism, blocking and suppression of the immune response of the body by immunosuppressive pathogens through their structural and non-structural products. Influenza a viruses, because of frequent and persistent mutations, produce a large number of variants, which severely threatens the immune barrier effect of the vaccine.
Disclosure of Invention
The technical problem to be solved by the invention is that a T cell epitope peptide for a universal influenza A virus vaccine is not developed in the field of influenza A virus at present.
The technical scheme of the invention is that the antigen epitope peptide of the influenza A virus CD8+T cell has an amino acid sequence shown as SEQ ID No. 11.
Furthermore, the invention also provides a nucleic acid molecule encoding the epitope peptide.
The invention also provides an influenza A virus CD8+T cell epitope peptide composition, which comprises an epitope peptide with an amino acid sequence shown as SEQ ID No.11 and at least one epitope peptide with an amino acid sequence shown as SEQ ID No.3, SEQ ID No.6 or SEQ ID No. 10.
Furthermore, the invention also provides a nucleic acid molecule encoding the antigen epitope peptide composition.
The invention also provides a pMHC complex containing the epitope peptide or the epitope peptide composition.
Further, the pMHC complex is obtained by renaturation of HLA-A2 heavy chain, HLA-A2 light chain beta 2m and the antigen epitope peptide.
Wherein the molar ratio of HLA-A2 heavy chain, HLA-A2 light chain beta 2m and the epitope peptide is 1:2:10.
The invention further provides an antigen peptide-antigen presenting cell complex, which is an antigen presenting cell with the surface loaded with the antigen epitope peptide or the antigen epitope peptide composition.
Wherein the antigen presenting cells are cd8+ T cells.
Preferably, the CD8+ T cells are T2-A2 cells.
The invention also provides the application of the antigen epitope peptide, the antigen epitope peptide composition, a nucleic acid molecule encoding the antigen epitope peptide or the antigen epitope peptide composition, the pMHC complex and/or the antigen peptide-antigen presenting cell complex in preparing influenza A virus medicaments.
The invention also provides the application of the antigen epitope peptide, the antigen epitope peptide composition, a nucleic acid molecule encoding the antigen epitope peptide or the antigen epitope peptide composition, a pMHC complex and/or an antigen peptide-antigen presenting cell complex in screening influenza A virus drugs.
The invention further provides the antigen epitope peptide, the antigen epitope peptide composition, a nucleic acid molecule encoding the antigen epitope peptide or the antigen epitope peptide composition, a pMHC complex and/or an antigen peptide-antigen presenting cell complex, and application thereof in preparing influenza A virus vaccines.
The invention further provides the application of the antigen epitope peptide, the antigen epitope peptide composition, a nucleic acid molecule encoding the antigen epitope peptide or the antigen epitope peptide composition, a pMHC complex and/or an antigen peptide-antigen presenting cell complex in preparing a medicament for evaluating the vaccination effect of influenza A virus.
The invention has the beneficial effects that: the invention provides an influenza A virus T cell epitope peptide which has strong immunogenicity and can induce antigen-specific CD8+T cells; it can assemble into pMHC complex with HLA-A2 heavy chain and HLA-A2 light chain beta 2m protein; or directly loaded to antigen presenting cells, can activate T cells, effectively induce T cell immunity, avoid immune escape of influenza A virus mutant strains, and can detect specific CD8+ T cells in influenza vaccinators and rehabilitators, thereby being applicable to research and development of influenza A virus universal vaccines, preparation, drug research and development and clinical treatment.
The invention also utilizes the influenza A virus CD8+ T cell epitope peptide to prepare a pMHC compound with a PE fluorescent channel, can be used for detecting antigen-specific T cells in peripheral blood of influenza A virus vaccinators and infection rehabilitators and is used for in-vitro T cell activation experiments, and the influenza A virus CD8+ T cell epitope peptide can be used for preparing general vaccines aiming at various influenza A virus mutant strains, immune detection related to influenza A viruses and broad-spectrum therapeutic medicaments. The influenza A virus CD8+ T cell epitope peptide is prepared into a pMHC complex with a PE fluorescent channel, or directly loaded to antigen presenting cells, so that T cells are activated, and the antigen presenting cell can be used for research and development of influenza A virus vaccines, preparation and drug research and development, and clinical treatment, and can be applied to:
1) Development and preparation of influenza a virus vaccine: after influenza A virus is mutated, the plurality of T cell epitopes can induce the body to generate immune response to generate antigen-specific T cells. Therefore, the T cell epitope is a candidate antigen epitope peptide of the influenza A virus universal vaccine.
2) Detecting whether it has cellular immune function against influenza a virus infection: the antigen-specific T cells of the influenza A virus are detected in the body of a person to be detected, which represents that the body has generated T cell immune function, and the intensity of the T cell immune function of the body and the possibility of infection to the influenza A virus can be evaluated according to the proportion of the antigen-specific CD8+T marked by the pMHC complex prepared into the fluorescent channel by the epitope peptide.
3) The effect after vaccination was evaluated: the detection of influenza a virus antigen specific T cells in the vaccinator, which represents that the body has developed T cell immune function, can be used to assess the likelihood of the body re-infecting influenza a virus.
4) Monitoring the condition: can be used for monitoring the change of the illness state of the close contact person, the medical observer, the suspected and the diagnosed patient.
5) And (3) prognosis judgment: poor prognosis is predicted if the body fails to mount a T cell immune response, or the proportion of antigen-specific T cells continues to decrease.
Drawings
FIG. 1, screening and identification of Influenza A Virus (IAV) T cell epitopes, A and B are T2 stability experiments. A is flow cytometry detection against β2m, and B is a statistical plot of A. C: results of the light-sensitive peptide displacement assay ELISA. Blank (Blank): no peptides; negative ctrl (Negative control): EBV virus peptide IVTDFSVIK; positive ctrl (Positive control), influenza a M1 peptide GILGFVFTL (below).
FIG. 2, preparation of pMHC complexes of HLA-A 2. A is the result of purifying the pMHC complex molecular sieve (Sephacryl S-200) in four different samples (numbered 1,2,3,4 in the figure), and numbers 1-4 represent the first through fourth peaks collected. B is a 15% SDS-PAGE result of Coomassie blue staining; m: protein molecular weight markers, numbers 1-4 in the figure correspond to peaks 1-4 in panel A, where red labeled 2 represents the peak of interest, heavy (a) and light (β2m) chains of HLA.
FIG. 3, immunogenicity identification of T cell epitopes of influenza A virus. A and B: detection of CD69 (upper row) and CD137 (lower row) molecules after 16 hours, B is a statistical plot of a.
FIG. 4, antigen-specific T cell production detected after mixed stimulation of epitopes; antigen-specific T cell production was detected by pMHC complexes with fluorescent channels after 0 day (top row) and 7 days (bottom row) of epitope mixed stimulation of healthy human cd8+ T cells, and B was a statistical plot of a.
Figure 5, epitope-stimulated T cell-mediated T2 apoptosis ratio. a-B (upper row): percentage of apoptosis of T2A2 cells stimulated for 7 days of culture; percent T2A2 apoptosis at day 7 (bottom row).
FIG. 6, detection of IFN-. Gamma. (upper row) and Granzyme B (lower row) expression in activated CD8+ T cells (A). B is a statistical graph of A.
FIG. 7, evaluation of the proportion of specific CD8+ T cells in vivo 14 days after influenza inactivated vaccination and 7 days after influenza A virus infection in convalescence patients; a-B: flow cytometry detected specific cd8+ T cells of the above 4 (antigen-specific cd8+ T epitopes that can be generated upon T cell activation) peptides from the HLA-A2+ influenza inactivated vaccine; C-D: flow cytometry examined the specific cd8+ T cells of the 4 above (antigen-specific cd8+ T epitopes that can be produced upon T cell activation) peptides from the HLA-A2+ influenza a virus infection healer.
Detailed Description
T2-A2 cells are an antigen presenting cell line expressing human MHC class I molecule HLa-A2 by recombinant genetic engineering techniques. Only effective epitope peptides can be presented, so that a stable pMHC complex is formed on the cell surface, and therefore, the antigen peptide can be used as artificial antigen presenting cells for stimulating T cells.
T cell epitope peptides alone cannot work and must be activated in the manner of pMHC complexes or antigen peptide-antigen presenting cell complexes. The invention utilizes MHC monomer and identified influenza A virus T cell epitope to carry out joint renaturation, thus preparing the pMHC complex. The identified antigen epitope peptide of the influenza A virus T cell is loaded on the surface of an antigen presenting cell (T2-A2 cell) to prepare an antigen peptide-antigen presenting cell complex, and then the prepared pMHC complex is used for labeling CD8+ T cells, so that the antigen epitope peptide can effectively activate T cells in peripheral blood of healthy people, has strong immunogenicity and can also effectively kill target cells carrying influenza A virus antigens. The pMHC complex with PE fluorescent channel assembled by the T cell epitope peptide can be detected in influenza A virus vaccinators and rehabilitators. The newly discovered antigen epitope peptide of the influenza A virus CD8+T cell can effectively induce T cell immunity, avoid immune escape of virus mutation, and can be used as a general vaccine or applied to immunotherapy and the like.
The invention will be further described in detail with reference to the drawings and specific examples, which are given solely for the purpose of illustration and are not intended to limit the scope of the invention. The test methods used in the following examples are conventional methods unless otherwise specified; the materials, reagents and the like used, unless otherwise specified, are those commercially available.
Example 1 prediction of influenza A Virus HLA-A2 restriction epitope peptide
HLA-A2 restriction epitope prediction was performed using MHC class I molecular prediction tools (http:// tools. IEDB. Org/mhci /) provided by the United states NIH epitope database (IEDB). The volunteers recruited were vaccinated with influenza A virus split vaccine using strain WHO and European UnionPopular strains of recommended influenza A type 1, A3 and B (2021/2022) or similar strains (northern hemisphere). The main components of the vaccine are antigens (an A/Victoria/2570/2019 (H1N 1) pdm09; an A/Cambodia/e0826360/2020 (H3N 2) containing the following strains (2021/2022); a B/Washington/02/2019 (B/Victoria line) -like viruses). The most common H1N1 and H3N2 are selected to find the corresponding sequence numbers (EPI_ISL_417210; EPI_ISL_806547) in the Gisaid database for predicting the epitope protein. Finally obtaining 11 candidate CD8 of the influenza A virus specificity HLA-A2+ + T cell epitope peptides are shown in Table 1.
TABLE 1 influenza A virus T cell 11 epitope peptides
| Numbering device | Start position | End position | Length of | Sequence(s) | Sequence number |
| F1 | 413 | 421 | 9 | NMLSTVLGV | SEQ ID No.1 |
| F2 | 46 | 54 | 9 | FMYSDFHFI | SEQ ID No.2 |
| F3 | 18 | 26 | 9 | STICFFMQI | SEQ ID No.3 |
| F4 | 275 | 283 | 9 | CLPACVYGL | SEQ ID No.4 |
| F5 | 373 | 381 | 9 | AMDSNTLEL | SEQ ID No.5 |
| F6 | 24 | 32 | 9 | MQIAILITT | SEQ ID No.6 |
| F7 | 458 | 466 | 9 | FQGRGVFEL | SEQ ID No.7 |
| F8 | 122 | 130 | 9 | AIMDKNIIL | SEQ ID No.8 |
| F9 | 218 | 226 | 9 | CVNGSCFTV | SEQ ID No.9 |
| F10 | 249 | 257 | 9 | KADTKILFI | SEQ ID No.10 |
| F11 | 128 | 136 | 9 | IVLEANFSV | SEQ ID No.11 |
Example 2 identification of influenza A Virus HLA-A2 restriction epitope peptide
Candidate T cell epitope peptides predicted in example 1 (Nanjing gold sry biotechnology Co., ltd.) were prepared at a concentration of 20. Mu.M. Taking logarithmic growth state T2-A2 fineCells (T2-A2 is a gift from Anna Gil doctor, university of Massachusetts medical school (University of Massachusetts Medical School)) were seeded into 96-well plates, 10 per well 5 Blank wells, negative control peptide (EB virus, IVTDFSVIK), positive control peptide (influenza A M1 peptide, SEQ ID No.12: GILGFVFTL) and each synthetic candidate T cell epitope peptide were distributed, 3 duplicate wells per group, and a final volume of 200. Mu.L. After incubation for 4 hours at 37℃the cells were washed twice by centrifugation, labeled with FITC anti-human HLA-A2 (. Beta.2m) antibodies, incubated at 4℃for 30 minutes in the absence of light and then detected by flow cytometry. Experiments were performed 3 times in total.
The results are shown in FIGS. 1A and B, which show that 11 antigen polypeptides can be efficiently presented by antigen presenting cells to T cells, indicating that these peptides are T cell epitope peptides.
Example 3 detection of antigen Polypeptides to form pMHC complexes
The 11 influenza a virus T cell epitope peptides screened in example 2 were detected by ELISA. The specific operation is as follows:
100. Mu.L of 0.5. Mu.g mL was used at room temperature -1 Streptavidin was incubated on 96U-plates for 16-18 hours, washed 3 times with wash buffer (BioLegend, cat #420201, U.S.), and blocked with dilution buffer (0.5M Tris pH 8.0,1M NaCl,1% BSA,0.2% Tween 20) for 30 minutes at room temperature. The pMHC complex formed by the photoactive peptide (SEQ ID No.13: KILGFVFJV) and MHC ((BioLegend, cat #280003, US)) was used as HLA blank control, influenza A M1 peptide (GILGFVFTL) was used as positive control, and the EB virus peptide (SEQ ID No.14: IVTDFSVIK) was used as negative control. Then, 20. Mu.L of dilutions (400. Mu.M) of the 11 influenza virus T cell epitope peptides of example 1 and 20. Mu.L of dilutions of Flex-TTM monomer (200. Mu.g/mL) were each added to a 96-well plate, which were replaced with a 365nm three-way ultraviolet analyzer (Qian Bell, cat # 1903274), and incubated in a cell incubator at 37℃for 1 hour. After 3 washes with wash buffer, 100 μl of diluted HRP-binding antibody (BioLegend, cat#280303, us) was added and incubation was continued for 1 hour at 37 ℃ before washing. mu.L of substrate solution (10.34 mL deionized water, 1.2mL 0.1M citric acid monohydrate/trisodium citrate dihydrate, pH 4) was added0, 240. Mu.L 40mM ABTS, 120. Mu.L hydrogen peroxide solution) and incubated at room temperature in the dark for 8min. The reaction was quenched with 50. Mu.L of a termination solution (2% w/v oxalic acid dihydrate). Absorbance (OD value) was measured at a wavelength of 450nm with a microplate reader over 30 minutes.
The results are shown in FIG. 1C, which shows that all 11 antigen polypeptides can form pMHC complexes.
EXAMPLE 4 preparation of epitope peptide pMHC Complex monomer
The nucleotide sequences of HLA-A2 alpha chain and beta 2M are respectively constructed on a pET28a expression vector, transferred into escherichia coli BL21 (DE 3) for protein expression, nickel column (Biorad, cat#7324610, US) is used for purifying HLA-A2 protein (HLA-A 2 heavy chain a chain, HLA-A2 light chain beta 2M), the purified proteins HLA-A2 alpha chain protein, beta 2M protein and 11 epitope peptides in the table 1 in the example 1 are gradually dripped into 40mL of renaturation solution (5M urea, 0.4M arginine, 100mM Tris, 3.7mM cystamine, 6.3mM cysteamine and 2mM EDTA) according to the molar ratio of 1:2:10 respectively for renaturation, and the pMHC complex monomer of the epitope peptide is obtained.
The pMHC complex monomer was further purified by passing through DEAE ion exchange column, eluting with 0.5M NaCl, and collecting proteins according to the OD280nm uv absorbance peak. The proteins purified by DEAE ion exchange column were then purified by Superdex 75pg molecular sieve, eluted with PBS, and the different molecular weight proteins were collected according to the OD280nm UV absorbance peak. FIGS. 2A and 2B show that the antigen epitope peptide pMHC complex trimer (trimer of HLA-A2 heavy chain a chain+HLA-A 2 light chain β2m+antigen peptide) was obtained after purification.
Example 5 activation of T cells by influenza A Virus HLA-A2 restriction epitope peptide
T2 cells activate T cells by expressing HLa-A2 molecules (T2-A2, PMID:34414379; PMID:35194575; PMID:35116022; PMID: 37117789). Mononuclear lymphocytes (PBMCs) in peripheral venous blood of healthy volunteers were isolated and cd8+ T cells were further isolated. T2-A2 cells were labeled with CFSE and incubated with 11 different antigenic peptides from example 1 after 20 min treatment with 20. Mu.g/mL mitomycin.
The specific method comprises the following steps:
0.5X10 each well of a 96-well plate was seeded 6 0.5X10 of each CD8+ T cell was loaded with 11 epitope peptides of Table 1 6 T2-A2 cells were co-cultured (11 wells total) and co-stimulated with 1. Mu.g/mL anti-human CD28 antibody and 50IU/mL IL-2. 50IU/mL IL-2 and 20 mu M epitope peptide were supplemented every two days.
CD8+ T cells in peripheral venous blood of healthy volunteers were isolated and co-cultured with antigen polypeptide-loaded T2 cells, co-stimulated with 1. Mu.g/mL of anti-human CD28 antibody and 50IU/mL of IL-2, and the expression of T cell activating molecules CD69 and CD137 was detected after 16 hours of culture.
The pMHC complex monomer of 30 μl of the epitope peptide obtained in example 4 was mixed with 3.3 μl of PE streptavidin (BioLegend cat#405203, US) in a 96-well plate, and after incubation at 4 ℃ for 30 minutes in the dark, 2.4 μl of blocking solution (1.6 μl of 50mM biotin (Thermo Fisher, cat#b20656, US)) and 198.4 μl of PBS were added to stop the reaction, and incubated overnight at 4-8 ℃ to obtain pMHC complex with PE fluorescence channel.
After 7 days of culture, the percentage of survival of T2-A2, the proportion of specific CD8+ T cells labeled with pMHC complex with PE fluorescent channels and the percentage of apoptosis marker Annexin V-APC on T2-A2 cells were calculated and the release of IFN-gamma and GZMB from specific CD8+ T cells was examined. Percentage of IAV-mediated T2 apoptosis after 7 days in culture with cd8+ T cells: CFSE labeled T2A2 as target cells, the number of residual target cells was detected and calculated as 50% of T2 cells minus the percentage of surviving cells.
As shown in FIGS. 3A and 3B, the 11 influenza A virus T cell epitope peptides selected in example 2 were all capable of activating T cells. Wherein, the T cell epitope peptide KADTKILFI corresponding to the T cell epitope peptide STICFFMQI, F corresponding to the T cell epitope peptide MQIAILITT, F corresponding to the F3 and the T cell epitope peptide IVLEANFSV corresponding to the F11 have strong ability to activate cd8+ T cells, as shown in fig. 4A and 4B. Meanwhile, the specific CD8+T activated by the 11 peptides can kill target cells, as shown in FIGS. 5A and 5B; specific cd8+ T cells released IFN- γ and GZMB as shown in fig. 6A and 6B.
Example 6 activation of T cells by influenza A Virus HLA-A2 restriction epitope peptide
PBMCs in peripheral venous blood of volunteers 14 days after the second needle of the influenza a virus-vaccinated inactivated vaccine and 7 days after the influenza a virus-infected healed were isolated and HLA subtypes thereof were identified, and HLA-a2 positive PBMCs samples were further stained with pMHC complex with PE fluorescent channel and CD8-APC antibody in example 5, and then subjected to on-stream detection.
The results are shown in fig. 7, which shows that pMHC complexes with fluorescent channels of F3, F6, F10 and F11,4 epitope peptides can recognize antigen-specific cd8+ T cells generated in influenza a virus vaccinators (fig. 7A and 7B) and influenza a virus infection healers (fig. 7C and 7D).
It should be noted that the above embodiments are merely for illustrating the technical solution of the present invention and not for limiting the scope of the present invention, and that other various changes and modifications can be made by one skilled in the art based on the above description and the idea, and it is not necessary or exhaustive to all embodiments. Any modification, equivalent replacement, improvement, etc. which come within the spirit and principles of the invention are desired to be protected by the following claims.
Claims (8)
1. An influenza a virus cd8+ T cell epitope peptide, characterized in that: the amino acid sequence is shown as SEQ ID No. 11.
2. An influenza a virus cd8+ T cell epitope peptide composition characterized by: comprises an antigen epitope peptide with an amino acid sequence shown as SEQ ID No.11 and at least one antigen epitope peptide with an amino acid sequence shown as SEQ ID No.3, SEQ ID No.6 or SEQ ID No. 10.
3. A nucleic acid molecule encoding the epitope peptide of claim 1 or the epitope peptide composition of claim 2.
4. A pMHC complex containing the epitope peptide of claim 1, characterized in that: the pMHC complex is obtained by renaturation of HLA-A2 heavy chain, HLA-A2 light chain beta 2m and the antigen epitope peptide.
5. The pMHC complex according to claim 4, wherein: the molar ratio of HLA-A2 heavy chain, HLA-A2 light chain beta 2m and the epitope peptide is 1:2:10.
6. An antigenic peptide-antigen presenting cell complex, characterized by: an antigen presenting cell surface-loaded with the epitope peptide of claim 1; the antigen presenting cells are T2-A2 cells.
7. Use of the epitope peptide of claim 1, the epitope peptide composition of claim 2, the nucleic acid molecule of claim 3, the pMHC complex of claim 4 or 5 and/or the antigen peptide-antigen presenting cell complex of claim 6 in the preparation of an influenza a virus drug or in the screening of an influenza a virus drug.
8. Use of an epitope peptide according to claim 1, an epitope peptide composition according to claim 2, a nucleic acid molecule according to claim 3, a pMHC complex according to claim 4 or 5 and/or an antigen peptide-antigen presenting cell complex according to claim 6 for the preparation of an influenza a virus vaccine or for the preparation of a medicament for assessing the vaccination effect of an influenza a virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311379350.9A CN117402214B (en) | 2023-10-24 | 2023-10-24 | Influenza A virus CD8+ T cell epitope peptide and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311379350.9A CN117402214B (en) | 2023-10-24 | 2023-10-24 | Influenza A virus CD8+ T cell epitope peptide and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117402214A CN117402214A (en) | 2024-01-16 |
| CN117402214B true CN117402214B (en) | 2024-03-19 |
Family
ID=89488456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311379350.9A Active CN117402214B (en) | 2023-10-24 | 2023-10-24 | Influenza A virus CD8+ T cell epitope peptide and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117402214B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111548396A (en) * | 2020-04-17 | 2020-08-18 | 暨南大学 | Novel coronavirus T cell epitope peptide, pMHC, preparation and application thereof |
| CN115960253A (en) * | 2022-08-30 | 2023-04-14 | 暨南大学 | Tumor T cell epitope peptide, pMHC, preparation and application thereof |
| CN116396366A (en) * | 2022-02-24 | 2023-07-07 | 暨南大学 | Novel coronavirus T cell epitope peptide and application thereof in preparation of vaccine |
-
2023
- 2023-10-24 CN CN202311379350.9A patent/CN117402214B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111548396A (en) * | 2020-04-17 | 2020-08-18 | 暨南大学 | Novel coronavirus T cell epitope peptide, pMHC, preparation and application thereof |
| CN116396366A (en) * | 2022-02-24 | 2023-07-07 | 暨南大学 | Novel coronavirus T cell epitope peptide and application thereof in preparation of vaccine |
| CN115960253A (en) * | 2022-08-30 | 2023-04-14 | 暨南大学 | Tumor T cell epitope peptide, pMHC, preparation and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 自身肽结合于HLA-A2分子上能够在体外诱导抗原肽特异性的同种T细胞;翁秀芳等;中国科学(C辑:生命科学);20070215;第37卷(第01期);第73-81页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117402214A (en) | 2024-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114751965B (en) | Novel coronavirus T cell epitope peptide and application thereof in preparation of vaccine | |
| Grifoni et al. | Global assessment of dengue virus-specific CD4+ T cell responses in dengue-endemic areas | |
| CN111548396B (en) | Novel coronavirus T cell epitope peptide, pMHC, preparation and application thereof | |
| CN114656529B (en) | Novel antigen epitope peptide of coronavirus T cell and application thereof | |
| CN106397574A (en) | Antigen epitope peptide and application thereof | |
| Hamrouni et al. | Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects | |
| CN117486999A (en) | Tumor T cell epitope peptide, pMHC, and preparation and application thereof | |
| CN117402214B (en) | Influenza A virus CD8+ T cell epitope peptide and application thereof | |
| Selvavinayagam et al. | Factors associated with the decay of anti-SARS-CoV-2 S1 IgG antibodies among recipients of an adenoviral vector-based AZD1222 and a whole-virion inactivated BBV152 vaccine | |
| CN117430664B (en) | Influenza A virus T cell epitope peptide and application thereof | |
| CN117402213B (en) | Influenza A virus CD8+ T cell epitope peptide and application thereof | |
| WO2014165866A2 (en) | Methods for immune-based diagnosis, prevention and personalized treatment of narcolepsy | |
| CN117430665B (en) | Influenza A virus T cell epitope peptide and application thereof | |
| CN108440656B (en) | Application of mycobacterium tuberculosis PKA protein and fusion protein thereof in auxiliary diagnosis of pulmonary tuberculosis | |
| CN101370513A (en) | Immunogenicity polypeptide composed of optimized concealed peptide derived from tumor antigen | |
| Baranek et al. | Plasmacytoid Dendritic Cells, the Control of Herpesvirus Infections | |
| US20210338806A1 (en) | METHODS OF GENERATING VACCINES AGAINST NOVEL CORONAVIRUS, NAMED SARS-COV-2 COMPRISING VARIABLE EPITOPE LIBRARIES (VELs) AS IMMUNOGENS | |
| CN107141355B (en) | HTNV (human immunodeficiency Virus) antigen epitope linear tandem polypeptide, epitope peptide-compound tetramer and application | |
| JP6622326B2 (en) | Influenza A / Shanghai / 2/2013 modified H7 hemagglutinin glycoprotein of H7 sequence | |
| Phan et al. | Cytotoxic T cells targeting spike glycoprotein are associated with hybrid immunity to SARS-CoV-2 | |
| Saruhan-Direskeneli et al. | Human HSP 60 peptide responsive T cell lines are similarly present in both Behcet's disease patients and healthy controls | |
| Hayney | Pharmacogenomics and infectious diseases: impact on drug response and applications to disease management | |
| US20040141995A1 (en) | MHC class I-restricted and MHC class II-restricted EBNA1 peptides | |
| Alqahtani et al. | Aim2 and Nlrp3 are dispensable for vaccine-induced immunity against Francisella tularensis live vaccine strain | |
| US20190105386A1 (en) | Methods for improving the efficacy of vaccine antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |